Boehringer Ingelheim has entered into a contract development and manufacturing agreement with AnGes Inc. for the active pharmaceutical ingredient of AnGes’ investigational Hepatocyte Growth Factor (HGF) gene therapy. The therapy is being developed for the treatment of Peripheral Arterial Disease
Cambrex, a global contract development and manufacturing organisation (CDMO), announced that its subsidiary Snapdragon Chemistry has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts. The expansion adds a new GMP manufacturing suite and increases the overall site footprint
Access to Advanced Health Institute (AAHI) has announced a partnership with Quratis, designating the biotechnology firm and Contract Development and Manufacturing Organization (CDMO) as its preferred manufacturer for vaccine supplies. Quratis will provide pre-clinical and clinical-grade production, with the potential
ProMed Pharma LLC, a provider of polymer-based drug delivery solutions, has acquired a 28,000 square foot pharmaceutical manufacturing facility in Plymouth, Minnesota. The site, formerly owned and operated by Bora Pharmaceuticals, adds to ProMed Pharma’s commercial manufacturing capabilities. The acquisition
Laurus Labs is undertaking a strategic restructuring of its contract development and manufacturing (CDMO) operations. The company is demerging Unit-1, the API manufacturing portion of Laurus Synthesis Pvt Ltd (LSPL), and merging the remaining LSPL business into Laurus Labs Ltd.
Andelyn Biosciences, a cell and gene therapy CDMO, has partnered with Amplo Biotechnology to enable scalable manufacturing of clinical-grade adeno-associated virus (AAV) material. The partnership targets neuromuscular junction (NMJ) disorders, which can cause severe muscle weakness and may require respiratory
Piramal Pharma Solutions, a global CDMO, and NewAmsterdam Pharma have launched a dedicated OSD form suite at the Sellersville, Pennsylvania, facility. The suite will support the production of NewAmsterdam Pharma’s investigational fixed-dose combination therapy of obicetrapib and ezetimibe, a non-statin
Johnson & Johnson has announced plans to expand its U.S. manufacturing footprint with a 160,000+ square foot facility at Fujifilm‘s biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion investment over the next decade is expected to create
Catalent, a global CDMO, has announced the reduction of 350 positions in its gene therapy manufacturing division in Baltimore, citing an unexpected shift in demand from a major customer. The company stated that the layoffs were necessary to adjust its
ChemPartner, a global CRO and CDMO, has announced its strategic expansion in the U.S. with the opening of the Boston Center of Excellence. The 12,000-square-foot R&D site, located at 480 Arsenal Way in Watertown, Massachusetts, will commence operations on 10
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
